Next-generation gene therapy manufacturing to drive better in vivo outcomes: Improving vector quality and delivery efficiency to reduce dose requirements, improve safety, and achieve greater scalability
04 May 2026
Next Gen Vector Engineering & Delivery
- Is LVV heterogeneity actually a problem for innovators, or something we’ve learned to live with?
- Do current analytical methods give us enough confidence in what we’re manufacturing?
- What level of heterogeneity is acceptable from a clinical or regulatory perspective?
- As LVVs move toward in vivo use, are expectations around product characterization changing?
- Where are we most at risk of misunderstanding our product today?
Industry Expert
